Millipore xMap® Luminex (HATMAG-68K): An Accurate and Cost-Effective Method for Evaluating Alzheimer's Biomarkers in Cerebrospinal Fluid
Background: Alzheimer's disease (AD) biomarkers are of great relevance in clinical research, especially after the AT(N) framework. They enable early diagnosis, disease staging and research with new promising drugs, monitoring therapeutic response. However, the high cost and low availability of...
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-08-01
|
Series: | Frontiers in Psychiatry |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fpsyt.2021.716686/full |
id |
doaj-d24628b7ebb84afe9364f2ce9f2d915e |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Erika Oliveira Hansen Erika Oliveira Hansen Natalia Silva Dias Natalia Silva Dias Ivonne Carolina Bolaños Burgos Monica Vieira Costa Andréa Teixeira Carvalho Antonio Lucio Teixeira Antonio Lucio Teixeira Izabela Guimarães Barbosa Izabela Guimarães Barbosa Izabela Guimarães Barbosa Lorena Aline Valu Santos Daniela Valadão Freitas Rosa Aloisio Joaquim Freitas Ribeiro Bernardo Mattos Viana Bernardo Mattos Viana Bernardo Mattos Viana Maria Aparecida Camargos Bicalho Maria Aparecida Camargos Bicalho Maria Aparecida Camargos Bicalho Maria Aparecida Camargos Bicalho Maria Aparecida Camargos Bicalho |
spellingShingle |
Erika Oliveira Hansen Erika Oliveira Hansen Natalia Silva Dias Natalia Silva Dias Ivonne Carolina Bolaños Burgos Monica Vieira Costa Andréa Teixeira Carvalho Antonio Lucio Teixeira Antonio Lucio Teixeira Izabela Guimarães Barbosa Izabela Guimarães Barbosa Izabela Guimarães Barbosa Lorena Aline Valu Santos Daniela Valadão Freitas Rosa Aloisio Joaquim Freitas Ribeiro Bernardo Mattos Viana Bernardo Mattos Viana Bernardo Mattos Viana Maria Aparecida Camargos Bicalho Maria Aparecida Camargos Bicalho Maria Aparecida Camargos Bicalho Maria Aparecida Camargos Bicalho Maria Aparecida Camargos Bicalho Millipore xMap® Luminex (HATMAG-68K): An Accurate and Cost-Effective Method for Evaluating Alzheimer's Biomarkers in Cerebrospinal Fluid Frontiers in Psychiatry Alzheimer's disease biomarker Millipore xMap® Luminex cerebrospinal fluid Aβ42 tau |
author_facet |
Erika Oliveira Hansen Erika Oliveira Hansen Natalia Silva Dias Natalia Silva Dias Ivonne Carolina Bolaños Burgos Monica Vieira Costa Andréa Teixeira Carvalho Antonio Lucio Teixeira Antonio Lucio Teixeira Izabela Guimarães Barbosa Izabela Guimarães Barbosa Izabela Guimarães Barbosa Lorena Aline Valu Santos Daniela Valadão Freitas Rosa Aloisio Joaquim Freitas Ribeiro Bernardo Mattos Viana Bernardo Mattos Viana Bernardo Mattos Viana Maria Aparecida Camargos Bicalho Maria Aparecida Camargos Bicalho Maria Aparecida Camargos Bicalho Maria Aparecida Camargos Bicalho Maria Aparecida Camargos Bicalho |
author_sort |
Erika Oliveira Hansen |
title |
Millipore xMap® Luminex (HATMAG-68K): An Accurate and Cost-Effective Method for Evaluating Alzheimer's Biomarkers in Cerebrospinal Fluid |
title_short |
Millipore xMap® Luminex (HATMAG-68K): An Accurate and Cost-Effective Method for Evaluating Alzheimer's Biomarkers in Cerebrospinal Fluid |
title_full |
Millipore xMap® Luminex (HATMAG-68K): An Accurate and Cost-Effective Method for Evaluating Alzheimer's Biomarkers in Cerebrospinal Fluid |
title_fullStr |
Millipore xMap® Luminex (HATMAG-68K): An Accurate and Cost-Effective Method for Evaluating Alzheimer's Biomarkers in Cerebrospinal Fluid |
title_full_unstemmed |
Millipore xMap® Luminex (HATMAG-68K): An Accurate and Cost-Effective Method for Evaluating Alzheimer's Biomarkers in Cerebrospinal Fluid |
title_sort |
millipore xmap® luminex (hatmag-68k): an accurate and cost-effective method for evaluating alzheimer's biomarkers in cerebrospinal fluid |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Psychiatry |
issn |
1664-0640 |
publishDate |
2021-08-01 |
description |
Background: Alzheimer's disease (AD) biomarkers are of great relevance in clinical research, especially after the AT(N) framework. They enable early diagnosis, disease staging and research with new promising drugs, monitoring therapeutic response. However, the high cost and low availability of the most well-known methods limits their use in low and medium-income countries. In this context, Millipore xMap® Luminex may be a cost-effective alternative. In our study, using INNOTEST® as reference, we assess the diagnostic accuracy of Millipore xMap® and propose a cutoff point for AD.Methods: We performed lumbar puncture of seven older individuals with clinically defined AD, 17 with amnestic mild cognitive impairment (aMCI) and 11 without objective cognitive impairment-control group (CG). Cerebrospinal fluid (CSF) biomarkers concentrations for aB42, p-Tau, and t-Tau were measured by INNOTEST® and Millipore xMap®, and then the techniques were compared to assess the diagnostic accuracy of the new test and to define a cutoff.Results: INNOTEST® and Millipore xMap® measurements showed all correlations >0.8 for the same biomarker, except for t-Tau that was 0.66. Millipore xMap® measurements showed a robust accuracy for all biomarkers, with AUC higher than 0.808 (t-Tau), and the best for Aβ42 (AUC = 0.952). The most accurate cutoffs were found at 1012.98 pg/ml (Aβ42), 64.54 pg/ml (p-tau), 3251.81 pg/ml (t-tau), 3.370 (t-Tau/Aβ42), and 0.059 (p-Tau/Aβ42).Conclusion: Given its good accuracy and cost-effectiveness, Milliplex xMap® tests seems a reliable and promising tool, especially for low and middle-income countries. |
topic |
Alzheimer's disease biomarker Millipore xMap® Luminex cerebrospinal fluid Aβ42 tau |
url |
https://www.frontiersin.org/articles/10.3389/fpsyt.2021.716686/full |
work_keys_str_mv |
AT erikaoliveirahansen milliporexmapluminexhatmag68kanaccurateandcosteffectivemethodforevaluatingalzheimersbiomarkersincerebrospinalfluid AT erikaoliveirahansen milliporexmapluminexhatmag68kanaccurateandcosteffectivemethodforevaluatingalzheimersbiomarkersincerebrospinalfluid AT nataliasilvadias milliporexmapluminexhatmag68kanaccurateandcosteffectivemethodforevaluatingalzheimersbiomarkersincerebrospinalfluid AT nataliasilvadias milliporexmapluminexhatmag68kanaccurateandcosteffectivemethodforevaluatingalzheimersbiomarkersincerebrospinalfluid AT ivonnecarolinabolanosburgos milliporexmapluminexhatmag68kanaccurateandcosteffectivemethodforevaluatingalzheimersbiomarkersincerebrospinalfluid AT monicavieiracosta milliporexmapluminexhatmag68kanaccurateandcosteffectivemethodforevaluatingalzheimersbiomarkersincerebrospinalfluid AT andreateixeiracarvalho milliporexmapluminexhatmag68kanaccurateandcosteffectivemethodforevaluatingalzheimersbiomarkersincerebrospinalfluid AT antoniolucioteixeira milliporexmapluminexhatmag68kanaccurateandcosteffectivemethodforevaluatingalzheimersbiomarkersincerebrospinalfluid AT antoniolucioteixeira milliporexmapluminexhatmag68kanaccurateandcosteffectivemethodforevaluatingalzheimersbiomarkersincerebrospinalfluid AT izabelaguimaraesbarbosa milliporexmapluminexhatmag68kanaccurateandcosteffectivemethodforevaluatingalzheimersbiomarkersincerebrospinalfluid AT izabelaguimaraesbarbosa milliporexmapluminexhatmag68kanaccurateandcosteffectivemethodforevaluatingalzheimersbiomarkersincerebrospinalfluid AT izabelaguimaraesbarbosa milliporexmapluminexhatmag68kanaccurateandcosteffectivemethodforevaluatingalzheimersbiomarkersincerebrospinalfluid AT lorenaalinevalusantos milliporexmapluminexhatmag68kanaccurateandcosteffectivemethodforevaluatingalzheimersbiomarkersincerebrospinalfluid AT danielavaladaofreitasrosa milliporexmapluminexhatmag68kanaccurateandcosteffectivemethodforevaluatingalzheimersbiomarkersincerebrospinalfluid AT aloisiojoaquimfreitasribeiro milliporexmapluminexhatmag68kanaccurateandcosteffectivemethodforevaluatingalzheimersbiomarkersincerebrospinalfluid AT bernardomattosviana milliporexmapluminexhatmag68kanaccurateandcosteffectivemethodforevaluatingalzheimersbiomarkersincerebrospinalfluid AT bernardomattosviana milliporexmapluminexhatmag68kanaccurateandcosteffectivemethodforevaluatingalzheimersbiomarkersincerebrospinalfluid AT bernardomattosviana milliporexmapluminexhatmag68kanaccurateandcosteffectivemethodforevaluatingalzheimersbiomarkersincerebrospinalfluid AT mariaaparecidacamargosbicalho milliporexmapluminexhatmag68kanaccurateandcosteffectivemethodforevaluatingalzheimersbiomarkersincerebrospinalfluid AT mariaaparecidacamargosbicalho milliporexmapluminexhatmag68kanaccurateandcosteffectivemethodforevaluatingalzheimersbiomarkersincerebrospinalfluid AT mariaaparecidacamargosbicalho milliporexmapluminexhatmag68kanaccurateandcosteffectivemethodforevaluatingalzheimersbiomarkersincerebrospinalfluid AT mariaaparecidacamargosbicalho milliporexmapluminexhatmag68kanaccurateandcosteffectivemethodforevaluatingalzheimersbiomarkersincerebrospinalfluid AT mariaaparecidacamargosbicalho milliporexmapluminexhatmag68kanaccurateandcosteffectivemethodforevaluatingalzheimersbiomarkersincerebrospinalfluid |
_version_ |
1717815849416392704 |
spelling |
doaj-d24628b7ebb84afe9364f2ce9f2d915e2021-09-03T20:12:02ZengFrontiers Media S.A.Frontiers in Psychiatry1664-06402021-08-011210.3389/fpsyt.2021.716686716686Millipore xMap® Luminex (HATMAG-68K): An Accurate and Cost-Effective Method for Evaluating Alzheimer's Biomarkers in Cerebrospinal FluidErika Oliveira Hansen0Erika Oliveira Hansen1Natalia Silva Dias2Natalia Silva Dias3Ivonne Carolina Bolaños Burgos4Monica Vieira Costa5Andréa Teixeira Carvalho6Antonio Lucio Teixeira7Antonio Lucio Teixeira8Izabela Guimarães Barbosa9Izabela Guimarães Barbosa10Izabela Guimarães Barbosa11Lorena Aline Valu Santos12Daniela Valadão Freitas Rosa13Aloisio Joaquim Freitas Ribeiro14Bernardo Mattos Viana15Bernardo Mattos Viana16Bernardo Mattos Viana17Maria Aparecida Camargos Bicalho18Maria Aparecida Camargos Bicalho19Maria Aparecida Camargos Bicalho20Maria Aparecida Camargos Bicalho21Maria Aparecida Camargos Bicalho22Jenny de Andrade Faria Institute– Reference Center for the Elderly, Hospital das Clínicas, Universidade Federal de Minas Gerais, Belo Horizonte, BrazilMolecular Medicine Program, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, BrazilNeuroscience Program, Institute of Biological Sciences, Universidade Federal de Minas Gerais, Belo Horizonte, BrazilElderly Psychiatry and Psychology Extension Program (PROEPSI), Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, BrazilAdult Health Sciences Applied Program, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, BrazilMolecular Medicine Program, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, BrazilRené Rachou Institute, Oswaldo Cruz Foundation (Fiocruz), Belo Horizonte, BrazilDepartment of Psychiatry and Behavioral Sciences, UT Health, Houston, TX, United StatesInstituto de Ensino e Pesquisa, Santa Casa de Belo Horizonte, Belo Horizonte, BrazilNeuroscience Program, Institute of Biological Sciences, Universidade Federal de Minas Gerais, Belo Horizonte, BrazilElderly Psychiatry and Psychology Extension Program (PROEPSI), Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, BrazilDepartment of Mental Health, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil0National Institute of Science and Technology of Molecular Medicine (INCT-MM), Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil0National Institute of Science and Technology of Molecular Medicine (INCT-MM), Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil1Institute of Exact Sciences, Statistics Department, Universidade Federal de Minas Gerais, Belo Horizonte, BrazilJenny de Andrade Faria Institute– Reference Center for the Elderly, Hospital das Clínicas, Universidade Federal de Minas Gerais, Belo Horizonte, BrazilElderly Psychiatry and Psychology Extension Program (PROEPSI), Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, BrazilDepartment of Mental Health, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, BrazilJenny de Andrade Faria Institute– Reference Center for the Elderly, Hospital das Clínicas, Universidade Federal de Minas Gerais, Belo Horizonte, BrazilMolecular Medicine Program, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, BrazilElderly Psychiatry and Psychology Extension Program (PROEPSI), Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil0National Institute of Science and Technology of Molecular Medicine (INCT-MM), Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil2Department of Clinical Medicine, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, BrazilBackground: Alzheimer's disease (AD) biomarkers are of great relevance in clinical research, especially after the AT(N) framework. They enable early diagnosis, disease staging and research with new promising drugs, monitoring therapeutic response. However, the high cost and low availability of the most well-known methods limits their use in low and medium-income countries. In this context, Millipore xMap® Luminex may be a cost-effective alternative. In our study, using INNOTEST® as reference, we assess the diagnostic accuracy of Millipore xMap® and propose a cutoff point for AD.Methods: We performed lumbar puncture of seven older individuals with clinically defined AD, 17 with amnestic mild cognitive impairment (aMCI) and 11 without objective cognitive impairment-control group (CG). Cerebrospinal fluid (CSF) biomarkers concentrations for aB42, p-Tau, and t-Tau were measured by INNOTEST® and Millipore xMap®, and then the techniques were compared to assess the diagnostic accuracy of the new test and to define a cutoff.Results: INNOTEST® and Millipore xMap® measurements showed all correlations >0.8 for the same biomarker, except for t-Tau that was 0.66. Millipore xMap® measurements showed a robust accuracy for all biomarkers, with AUC higher than 0.808 (t-Tau), and the best for Aβ42 (AUC = 0.952). The most accurate cutoffs were found at 1012.98 pg/ml (Aβ42), 64.54 pg/ml (p-tau), 3251.81 pg/ml (t-tau), 3.370 (t-Tau/Aβ42), and 0.059 (p-Tau/Aβ42).Conclusion: Given its good accuracy and cost-effectiveness, Milliplex xMap® tests seems a reliable and promising tool, especially for low and middle-income countries.https://www.frontiersin.org/articles/10.3389/fpsyt.2021.716686/fullAlzheimer's diseasebiomarkerMillipore xMap® Luminexcerebrospinal fluidAβ42tau |